FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer
On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non- …